Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Visitors trend2W10W9M

231.27

-1.58

(-0.68%)

As of 09:41AM EST. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Hanging Man

View all chart patterns

Performance Outlook

Previous Close	232.85
Open	234.11
Bid	220.00 x 800
Ask	234.50 x 800
Day's Range	230.84 - 232.48
52 Week Range	220.86 - 319.76
Volume	16,668
Avg. Volume	979,542

Market Cap	33.511B
Beta (5Y Monthly)	0.08
PE Ratio (TTM)	22.99
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIIB

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Biogen Inc.
Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Rating
Fair Value
Economic Moat
27 days agoMorningstar